TY - JOUR
T1 - RAS inhibitors
T2 - Potential for cancer therapeutics
AU - Kloog, Yoel
AU - Cox, Adrienne D.
N1 - Funding Information:
This work was supported in part by Grant 9700141 from the United States–Israel Binational Science Foundation, Jerusalem, Israel (to Y.K. and A.D.C.). The authors would like to acknowledge Hagit Niv for assisting in the preparation of the manuscript and the graphics. The authors apologize to all those colleagues whose work we were unable to cite owing to space constraints.
PY - 2000
Y1 - 2000
N2 - As RAS oncoproteins play a major role in human malignancy, inhibiting RAS function is a promising approach for developing anticancer therapies. Among these approaches are agents such as farnesyltransferase inhibitors (FTIs) and the nontoxic farnesylcysteine analogue farnesylthiosalicylic acid (FTS) that dislodges all RAS isoforms from the membrane, as well as methods to restore regulation of RAS-GTP levels and to alter the interaction of RAS-GTP with downstream targets.
AB - As RAS oncoproteins play a major role in human malignancy, inhibiting RAS function is a promising approach for developing anticancer therapies. Among these approaches are agents such as farnesyltransferase inhibitors (FTIs) and the nontoxic farnesylcysteine analogue farnesylthiosalicylic acid (FTS) that dislodges all RAS isoforms from the membrane, as well as methods to restore regulation of RAS-GTP levels and to alter the interaction of RAS-GTP with downstream targets.
UR - http://www.scopus.com/inward/record.url?scp=0033803477&partnerID=8YFLogxK
U2 - 10.1016/S1357-4310(00)01789-5
DO - 10.1016/S1357-4310(00)01789-5
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
AN - SCOPUS:0033803477
SN - 1357-4310
VL - 6
SP - 398
EP - 402
JO - Molecular Medicine Today
JF - Molecular Medicine Today
IS - 10
ER -